# Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct01338870` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01338870](<https://clinicaltrials.gov/study/NCT01338870>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01338870

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.

## Technical summary

Registry record NCT01338870. Randomized; double masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2013-04-23.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 301 participants (enrolled count; ClinicalTrials.gov record NCT01338870, source copy `cardio:ctgov-nct01338870-2013-04-23`, retrieved 2026-10-26)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01338870, source copy `cardio:ctgov-nct01338870-2013-04-23`, retrieved 2026-10-26)
- Primary completion: 2012-03 (actual) (ClinicalTrials.gov record NCT01338870, source copy `cardio:ctgov-nct01338870-2013-04-23`, retrieved 2026-10-26)
- Completion: 2012-03 (actual) (ClinicalTrials.gov record NCT01338870, source copy `cardio:ctgov-nct01338870-2013-04-23`, retrieved 2026-10-26)
- Results first posted: 2013-04-23 (ClinicalTrials.gov record NCT01338870, source copy `cardio:ctgov-nct01338870-2013-04-23`, retrieved 2026-10-26)
- Countries: United States; Canada; Hungary; Mexico; Slovakia; Taiwan (ClinicalTrials.gov record NCT01338870, source copy `cardio:ctgov-nct01338870-2013-04-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01338870-2013-04-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Placebo
- Intervention (Drug): 25 mg PF-04991532
- Intervention (Drug): 75 mg PF-04991532
- Intervention (Drug): 150 mg PF-04991532
- Intervention (Drug): 300 mg PF-04991532
- Intervention (Drug): Sitagliptin 100 mg
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: b0c2c5963d8f8f6b44dedcd75f003565d313a47ea0d715143d5c84c3b510d610
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
